Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.50 | N/A | +11.50% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.50 | N/A | +11.50% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results despite not providing revenue figures. They emphasized their commitment to pipeline development.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
IDEAYA Biosciences I's earnings report showed a smaller-than-expected loss per share, which pleased investors and led to a 6.17% increase in stock price. However, the lack of revenue data and guidance leaves some uncertainty about the company's financial health moving forward. Investors may be optimistic about the company's focus on its pipeline despite these gaps in information.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DAVE INC A
Mar 6, 2023